Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 10, 1999, Pages 997-1003

  Miyazono, Yuko ^a   Kamogawa, Yumiko ^a,b   Ryo, Kyouka ^a   Furukawa, Takaji ^a   Mitsuhashi, Maki ^a   Yamauchi, Katsumi ^a   Kameoka, Takanobu ^a   Hayashi, Naoaki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Co stimulatory signal; Cytotoxic T lymphocyte; Tumour immunity

Indexed keywords

INTERLEUKIN 2;

ADULT; ARTICLE; CANCER CELL; CASE REPORT; CELL PROLIFERATION; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HLA SYSTEM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

EID: 0032829426     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01990.x     Document Type: Article

References (26)

1. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol. Today 1994; 15: 321-31.
2. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995; 2: 555-9.
3. Chen C, Nabavi N. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1994; 1: 147-54.
4. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-56.
5. Hellstrom KE, Hellstrom I, Linsley P, Chen L. On the role of costimulation in tumor immunity. Ann. NY Acad. Sci. 1993; 690: 24-33.
6. Hellstrom KE, Hellstrom I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 1995; 145: 123-45.
7. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-70.
8. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl Acad. Sci. USA 1993; 90: 5687-90.
9. Yang G, Mizuno MT, Hellstrom KE, Chen L. B7-negative versus B7-positive P815 tumor differential requirements for priming of an antitumor immune response in lymph nodes. J. Immunol. 1997; 158: 851-8.
10. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994; 54: 6477-83.
11. Sule-Suso J, Arienti F, Melani C, Colombo MP, Parmiani G. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogenic lymphocytes. Eur. J. Immunol. 1995; 25: 2737-42.
12. Bain C, Merrouche Y, Puisieux I, Due A, Colombo MP, Favrot M. B7-1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogenic T cells. Int. J. Cancer 1996; 67: 769-76.
13. Kaufmann AM, Gissmann L, Street D, Schreckenberger C, Hunter M, Qio L. Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro. Cell Immunol. 1996; 169: 246-51.
14. Potter H, Weil L, Leder P. Enhancer-dependent expression of human κ immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc. Natl Acad. Sci. USA 1984; 81: 7161-5.
15. Ray JG, Hare DB, Pederson PD et al NIAID Manual of Tissue Typing Team, 1976-1977. Rockville, MD: Department of Health, Education and Welfare.
16. + T cells in vitro. J. Immnol. 1996; 156: 310-15.
17. Ishikawa T, Imawari M, Moriyama T et al. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2. J. Cancer Res. Clin. Oncol. 1988; 114: 283-90.
18. Koo AS, Tso CL, Shimabukuro T, Peyret C, Dekernion JB, Belldegrun A. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J. Immunother. 1991; 10: 347-54.
19. + T cell line. J. Immunother. 1992; 11: 1-11.
20. Aruga A, Yamauchi K, Takasaki K, FurukawaT, Hanyu F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int. J. Cancer 1991; 49: 19-24.
21. Visseren MJ, van der Burg SH, Hawes GE, van der Voort EI, van den Elsen PJ, Melief CJ. Affinity specificity and T-cell-receptor diversity of melanoma-specific CTL generated in vitro against a single tyrosinase epitope. Int. J. Cancer 1997; 72: 1122-8.
22. Mackensen A, Veelken H, Lahn M et al. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J. Mol. Med. 1997; 75: 290-6.
23. Haruta I, Yamauchi K, Aruga A et al. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: Comparison between LAK cell and CTL therapy. J. Immunother. 1996; 19: 218-23.
24. Cavallo F, Martin-Fontech A, Bellones M et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 1995; 25: 1154-62.
25. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 1993; 177: 1791-6.
26. Liu B, Podack ER, Allison JP, Malek TR. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. 1996; 156: 1117-25.